Stockholders to Vote on Multiple Highly Dilutive Financings and Equity Plan Expansion

summarizeSummary

Tivic Health Systems is asking shareholders to approve multiple highly dilutive financing deals and an expanded equity incentive plan, which could lead to over 99% dilution for existing stockholders.

check_boxKey Events

• Equity Incentive Plan Expansion Proposed

  Shareholders will vote on increasing the shares authorized for the 2021 Equity Incentive Plan by 2,581,608 shares, representing a potential 15.53% overhang on a pro-forma partially diluted basis.

• Series C Preferred & Warrants Approval Sought

  A vote is requested to approve the issuance of shares beyond the Nasdaq 19.99% cap for up to $75 million in Series C Preferred Stock and warrants, with the company stating this could result in over 99% dilution to current stockholders.

• Senior Secured Convertible Note & Warrant Approval

  Shareholders will vote to approve the issuance of shares beyond the Nasdaq 19.99% cap for a $16.25 million Senior Secured Convertible Note and warrant, with potential for significant dilution at a low floor price of $0.39.

• Series B Preferred & Warrants Approval

  A vote is requested to approve the issuance of shares beyond the Nasdaq 19.99% cap for up to $8.4 million in Series B Preferred Stock and warrants, with a conversion floor price of $0.39.

auto_awesomeAnalysis

Tivic Health Systems is seeking shareholder approval for several highly dilutive financing agreements and an expansion of its equity incentive plan. These proposals, if approved, would allow the company to issue a massive number of shares at significant discounts or low floor prices, leading to extreme dilution for existing stockholders. The company explicitly states that the Series C Preferred conversion and warrant exercise alone could result in over 99% dilution to current stockholders. The need for these approvals underscores the company's urgent requirement for capital, which it is securing on terms highly unfavorable to current equity holders. Failure to approve these proposals would severely limit the company's ability to access crucial funding, potentially jeopardizing its operations.